Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Nasopharyngeal Carcinoma 14Triple Negative Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Squamous Cell Carcinoma 9Breast Neoplasms 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Small Cell Lung Carcinoma 6Neoplasms 6Advanced Solid Tumor 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Recurrence 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Solid Tumor 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Turcot syndrome 2Sarcoma 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2NSCLC 2Muscle Invasive Bladder Cancer (MIBC) 2Carcinoma, Squamous Cell 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

famitinib 2camrelizumab 2toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Cancer Metastatic × toripalimab × 1 year × Clear all
NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Shanghai Jiatan Pharmatech Co., Ltd

Phase 3 Not yet recruiting
440 enrolled
Gynecologic

Cervical Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡